PB2032: MAGNETISMM-9: AN OPEN-LABEL, MULTICENTER, NON-RANDOMIZED PHASE 1/2 STUDY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
HemaSphere | June 24, 2022 | Volume: 6 | Issue: No issue available | Pages: 1903-1904
10.1097/01.hs9.0000850960.38950.59